1 / 12

NHS England commissioning update

NHS England commissioning update. Mandy Matthews. 14 th December 2018. Use of immunoglobulin in England. NHS England is responsible commissioner for immunoglobulin 2017/18 annual spend approaching £190 million in England Commissioned in line with national Clinical Guidelines

kisha
Download Presentation

NHS England commissioning update

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. NHS England commissioning update Mandy Matthews 14th December 2018

  2. Use of immunoglobulin in England • NHS England is responsible commissioner for immunoglobulin • 2017/18 annual spend approaching £190 million in England • Commissioned in line with national Clinical Guidelines • Significant supply issues in 2018 • Patient care • Resources required to manage supplies

  3. Significant risks: Availability – nationally & globally On-going growth in use CART-T Market share of products and risk if a supply issue; product choice Variation in use, e.g. indication, dose, frequency Decision making – how robust, variation in IAPs, IFRs Data

  4. Steps to manage risk: Improved collaborative working – Commercial medicines unit, clinicians, NHS England, Public Health England, MDSAS Immunoglobulin project working group Review of the current Clinical Guidelines for Immunoglobulin use Sub-regional Immunoglobulin Panels Proposed CQUIN for 2019/20 Proposed prior approval

  5. Guidelines review: • Launching 1st four sections: • Haematology • Immunology • Infectious diseases (specific) • Neurology • Next steps: • Review use in “other” indications, including other infection-related use • Review evidence for grey indications

  6. Sub-regional Immunoglobulin Assessment Panels (SRIAPs): Improve scrutiny & stewardship of immunoglobulin use Support demand management Manage usage within allocated volumes Improve communication channels in times of supply issues Compliance with NHS England commissioning guidance; review of existing patients; new patients Support data collection

  7. Immunoglobulin CQUIN: Provide funding to support the development of SRIAPs Role of SRIAPs in stewardship of immunoglobulin Ensure compliance with commissioning guidance Support implementation of prior approval

  8. Prior approval: • Automated system to approve use of Ig in line with updated guidance • Approval required prior to use • Options: • MDSAS national immunoglobulin database • Blueteq • How to incorporate this into trust processes

  9. Key messages: Importance of SRIAPs in managing demand New patients to meet eligibility criteria Review of existing patents in line with updated guidance Alternative therapies Data is key – usage & outcomes must be reported on the database

  10. Prior Approval In your groups consider the following: • Options: • MDSAS national immunoglobulin database • Blueteq • Pros and cons of each system? • Issues for providers? • What would support implementation?

  11. Sub-regional Immunoglobulin Panels In your groups consider: Progress so far Issues, concerns Resources required to support the panel

  12. Useful links: Rituximab, as a treatment option, in : Anti-NMDAR autoimmune encephalitis Cytopaeniacomplicating primary immunodeficiency Dermatomyositisand polymyositis ImmunobullousDisease Commissioning policies and position statements are available at: https://www.england.nhs.uk/specialised-commissioning-document-library/routinely-commissioned-policies/ and https://www.england.nhs.uk/specialised-commissioning-document-library/policy-statements-urgent-policy-statements/ Public Health England provides advice on use of immunoglobulin at: https://www.gov.uk/government/publications/immunoglobulin-when-to-use

More Related